Table 1.

Curated list of over- and under-expressed lncRNAs in selected breast cancer cell lines with their molecular subtypes. Previous associations with cancers are noted, along with publications.

lncRNAs over-expressed in breast cancer cell lines examined
lncRNA	RefSeq ID	Differentially expressed in:	Previous cancer association	References
CELF2-AS1	NR_126062.1	Basal A, Basal B	No cancer related publications
DSCAM-AS1	NR_038896.1	LA, LB, HER2 enriched, Basal A, ER/PR +ve, HER2 sensitive, triple negative	Breast and lung cancer	[15,36,[49], [50], [51], [52]]
ELFN1-AS1	NR_120508.1	DCIS, Basal A, Basal B	Expressed in various tumour samples	[53]
LINC00885	NR_034088.1	DCIS, Luminal B	Bladder cancer	[54]
LOC101448202	NR_103451.1	ER/PR +ve, triple negative	Uncharacterised
LOC105372471	XR_001754022.1	Basal A, Basal B, triple negative	Uncharacterised
LOC105372815	XR_937755.2	LA, LB, HER2 enriched, Basal A, HER2 sensitive, triple negative	Uncharacterised
MUC5B-AS1	NR_157183.1	LA, LB, HER2 enriched, ER/PR +ve, HER2 sensitive	Lung cancer	[55]
ZNF667-AS1	NR_036521.1	LA, Basal A, Basal B	Breast, cervical, oeosphageal, laryngeal cancer	[[56], [57], [58], [59], [60], [61]]
lncRNAs under-expressed in breast cancer cell lines examined
CCAT1	NR_108049.1	LA, LB, HER2 enriched, ER/PR +ve	Multiple cancers including acute myeloid leukaemia, breast, colon, gallbladder, liver and squamous cell carcinoma	[14,[62], [63], [64], [65], [66], [67], [68], [69], [70], [71]]
EGFR-AS1	NR_047551.1	Luminal B, ER/PR +ve,	Head & neck, lung, gastric and hepatocellular cancers	[[72], [73], [74], [75]]
LINC00885	NR_034088.1	Basal A	Bladder cancer	[54]
MIG7	NR_148965.1	HER2 enriched, ER/PR +ve, triple negative	Expressed in malignant cells; bone, hepatocellular and ovarian cancers	[[76], [77], [78], [79], [80]]
MUC5B-AS1	NR_157183.1	Basal B	Lung cancer	[55]
ZNF667-AS1	NR_036521.1	DCIS	Breast, cervical, oeosphageal, laryngeal cancer	[[56], [57], [58], [59], [60], [61]]